Informe de análisis del tamaño, la participación y las tendencias del mercado mundial de bronquiectasias: descripción general de la industria y pronóstico hasta 2031

Análisis del mercado de la bronquiectasia

El mercado de la bronquiectasia está experimentando un crecimiento significativo debido a la creciente prevalencia de enfermedades respiratorias y al aumento de la conciencia sobre el manejo de la bronquiectasia. Esta afección, caracterizada por una dilatación anormal de los bronquios, a menudo es resultado de infecciones crónicas y obstrucciones de las vías respiratorias. Los avances recientes en el diagnóstico, incluidas las técnicas avanzadas de diagnóstico por imágenes y la identificación de biomarcadores, han mejorado la detección temprana y las opciones de tratamiento personalizadas. El mercado comprende varias modalidades de tratamiento, incluidos medicamentos ( antibióticos , broncodilatadores y antiinflamatorios), fisioterapia e intervenciones quirúrgicas, que atienden las diversas necesidades de los pacientes. El auge de la telemedicina y las soluciones de salud digital también está mejorando la gestión del paciente y la atención de seguimiento. Los actores clave del mercado se están centrando en la investigación y el desarrollo para introducir terapias innovadoras y mejorar los resultados de los pacientes. Con el aumento del gasto sanitario y el envejecimiento de la población, el mercado de la bronquiectasia está preparado para la expansión, lo que promete mejores estrategias de gestión y una mejor calidad de vida para las personas afectadas.

Tamaño del mercado de la bronquiectasia

El tamaño del mercado global de bronquiectasias se valoró en USD 562,92 millones en 2023 y se proyecta que alcance los USD 904,00 millones para 2031, con una CAGR del 6,10% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Tendencias del mercado de la bronquiectasia

“ Aumento de la concienciación y avances en las opciones de tratamiento”

The market is evolving rapidly, driven by increasing awareness of the disease and advancements in treatment options. Recent innovations include the development of targeted therapies that aim to address the underlying causes of bronchiectasis rather than just alleviating symptoms. One notable trend is the rising adoption of personalized medicine, which tailors treatment plans based on individual patient profiles, including genetic factors and specific disease characteristics. This approach enhances the efficacy of interventions and minimizes side effects, leading to improved patient outcomes. Furthermore, advancements in diagnostic technologies, such as high-resolution computed tomography (HRCT) scans, allow for earlier and more accurate detection of the disease. The integration of telehealth services is also transforming patient management, facilitating regular monitoring and timely interventions. As research continues to unveil new therapeutic targets, the bronchiectasis market is set to expand, offering hope for more effective and personalized care for patients.

Report Scope and Bronchiectasis Market Segmentation       

Bronchiectasis Market Definition

Bronchiectasis is a chronic respiratory condition characterized by the abnormal and permanent dilation of the bronchial tubes, which are the airways that carry air to and from the lungs. This dilation results from the destruction of the elastic and muscular components of the bronchial wall, often caused by recurrent infections, inflammation, or obstructions. Patients with bronchiectasis may experience persistent cough, production of large amounts of mucus, shortness of breath, and frequent respiratory infections. The condition can be associated with various underlying diseases, including cystic fibrosis, chronic obstructive pulmonary disease (COPD), and immune system disorders.

Bronchiectasis Market Dynamics

Drivers

• Rising Incidence of Respiratory Conditions 

The rising incidence of respiratory conditions, such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and various respiratory infections, serves as a significant driver for the growth of the bronchiectasis market. These conditions contribute to a higher number of bronchiectasis cases globally, thereby increasing the demand for effective treatments. Cystic fibrosis, a hereditary disorder, often leads to recurrent lung infections and chronic inflammation, resulting in bronchiectasis development. In addition, COPD, characterized by chronic bronchitis and emphysema, damages lung tissue and predisposes individuals to bronchiectasis. Respiratory infections such as pneumonia and tuberculosis further exacerbate lung damage and the subsequent emergence of bronchiectasis. As the prevalence of these respiratory diseases continues to rise due to factors such as pollution, smoking, and an aging population, the bronchiectasis market will expand to meet the increasing demand for targeted therapies and management strategies.

• Advancements in Diagnostic Technologies

Improved diagnostic tools, such as high-resolution computed tomography (HRCT) and advanced imaging techniques, serve as a key driver for the growth of the bronchiectasis market. These advancements facilitate earlier detection and more effective management of the condition, which is crucial for enhancing patient outcomes. HRCT provides detailed images of the lungs, allowing healthcare providers to identify structural abnormalities associated with bronchiectasis, such as airway dilation and wall thickening. This enhanced diagnostic capability enables timely interventions and the implementation of tailored treatment strategies that cater to individual patient needs. Moreover, advanced imaging techniques assist in monitoring disease progression and evaluating the effectiveness of ongoing treatments. As the demand for early diagnosis rises, the bronchiectasis market is expected to expand, driven by the need for innovative therapies and management solutions that address the growing prevalence of the disease.

Opportunities

• Development of Advanced Drug Delivery Systems

The development of advanced drug delivery systems, such as inhalation therapies and nebulizers, presents a significant market opportunity in the management of bronchiectasis and other respiratory conditions. These innovative systems are designed to enhance medication delivery directly to the lungs, ensuring higher bioavailability and effectiveness. Inhalation therapies allow for a more patient-friendly administration method, making it easier for individuals to incorporate their treatments into daily routines. In addition, nebulizers convert liquid medication into a fine mist, enabling patients to inhale the medication comfortably over a longer duration, which is particularly beneficial for those experiencing severe symptoms or difficulties using traditional inhalers. By improving medication adherence and patient comfort, these advanced delivery systems lead to a more favorable treatment experience. This trend increases patient satisfaction and drives demand for innovative therapies, creating a lucrative growth opportunity for stakeholders in the bronchiectasis market.

• Emergence of Digital Health Technologies

The incorporation of digital health technologies, including mobile health apps and wearable devices, presents a significant market opportunity in the management of bronchiectasis. These innovative solutions enhance patient engagement and facilitate real-time monitoring of symptoms, leading to improved management and health outcomes. Mobile health apps empower patients to track their symptoms, medication adherence, and lifestyle factors, providing valuable insights that can be shared with healthcare providers. This interactive approach encourages active patient participation in their healthcare, promoting better adherence to treatment plans. Wearable devices, such as smartwatches and fitness trackers, can continuously monitor vital signs and detect early changes in respiratory function, alerting patients and healthcare providers to potential issues. Integrating these digital technologies into bronchiectasis care, stakeholders can tap into a growing market segment focused on personalized and effective management, ultimately enhancing patient quality of life and driving market growth.

Restraints/Challenges

• High Cost of Advanced Treatments and Diagnostic Tools

The cost of advanced treatments and diagnostic tools for bronchiectasis poses a significant barrier for both patients and healthcare systems, leading to disparities in access to care. Advanced therapies, such as targeted medications and innovative delivery systems, often come with high price tags that can be unaffordable for many patients, particularly those without adequate insurance coverage. This financial burden can result in patients delaying or forgoing necessary treatments, ultimately impacting their health outcomes. In addition, healthcare systems may struggle to allocate resources for costly diagnostic tools, such as high-resolution computed tomography (HRCT) scans, which are essential for accurate diagnosis and effective management of bronchiectasis. As a result, these economic challenges can create inequalities in access to quality care, limiting the overall market growth and hindering efforts to improve patient management and outcomes.

• Impact of Misdiagnosis on Bronchiectasis

Many cases of bronchiectasis remain undiagnosed or are misdiagnosed, primarily due to the overlap of symptoms with other respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and respiratory infections. Common symptoms such as chronic cough, wheezing, and sputum production can lead healthcare providers to attribute these signs to more prevalent conditions, causing bronchiectasis to be overlooked. This misdiagnosis delays appropriate treatment and limits the patient population actively seeking specialized care for bronchiectasis. Consequently, the lack of accurate diagnosis contributes to decreased awareness of the disease, affecting funding and resources allocated for research and treatment. As a result, this situation serves as a significant market restraint, as potential patients remain undiagnosed and untreated, further complicating their health outcomes and hindering overall growth in the bronchiectasis market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Bronchiectasis Market Scope

The market is segmented on the disease type, severity, type, drugs type, route of administration, and end user.The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

 Disease Type

• CF Bronchiectasis
• Non-CF Bronchiectasis

Severity

• Mild to Moderate
• Moderate-to-Severe

Type

• Diagnosis
• Treatment

Drugs Type

• Branded
• Generics

Route of Administration

• Oral
• Parenteral
• Inhalation

 End User

• Hospitals
• Clinics
• Home Healthcare
• Others

Bronchiectasis Market Regional Analysis

The market is analysed and market size insights and trends are provided by country disease type, severity, type, drugs type, route of administration, and end user as referenced above.

Los países cubiertos en el informe de mercado son EE. UU., Canadá y México en América del Norte, Alemania, Francia, Reino Unido, Países Bajos, Suiza, Bélgica, Rusia, Italia, España, Turquía, Resto de Europa en Europa, China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC), Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, Resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA), Brasil, Argentina y Resto de América del Sur como parte de América del Sur.

Se prevé que América del Norte lidere el mercado de la bronquiectasia, impulsada por un aumento en los ensayos clínicos y las iniciativas de investigación centradas en la prevención de enfermedades respiratorias graves en adultos. Esta región se beneficia de una sólida infraestructura sanitaria y de una importante inversión en soluciones de tratamiento innovadoras. Como resultado, se espera que los avances en investigación y desarrollo mejoren los resultados de los pacientes y consoliden la posición de América del Norte como actor clave en el mercado.

Se prevé que la región de Asia y el Pacífico experimente un crecimiento sustancial en el mercado de la bronquiectasia entre 2024 y 2031, impulsado por la creciente prevalencia de enfermedades respiratorias como el asma, la EPOC y la tuberculosis. Además, el aumento de la población geriátrica en esta región está contribuyendo a la demanda de opciones de tratamiento eficaces. A medida que los sistemas de atención sanitaria se esfuerzan por abordar estos desafíos, la necesidad de terapias innovadoras probablemente mejorará la expansión del mercado en Asia y el Pacífico.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como el análisis de la cadena de valor aguas abajo y aguas arriba, las tendencias técnicas y el análisis de las cinco fuerzas de Porter, los estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.  

Cuota de mercado de la bronquiectasia

El panorama competitivo del mercado proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos, y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado.

Los líderes del mercado de bronquiectasias que operan en el mercado son:

• Abbott (Estados Unidos)
• HERSILL (España)
• Inogen, Inc. (Estados Unidos)
• Boehringer Ingelheim International GmbH (Alemania)
• Medline Industries, Inc. (Estados Unidos)
• Ache Laboratorios Farmacéuticos SA (Brasil)
• Horizon Therapeutics plc (Irlanda)
• Janssen Pharmaceuticals, Inc. (Estados Unidos)
• Trudell Medical International (Canadá)
• GlaxoSmithKline plc (Estados Unidos)
• AstraZeneca (Reino Unido)
• Pfizer Inc. (Estados Unidos)
• Merck & Co., Inc. (Estados Unidos)
• Novartis AG (Suiza)
• Teva Pharmaceutical USA Inc. (Israel)
• Industrias farmacéuticas Sun Ltd. (India)
• Bayer AG (Alemania)
• Laboratorios Dr. Reddy Ltd. (India)
• Sunovion Pharmaceuticals Inc. (Estados Unidos)
• Viatris Inc. (Estados Unidos)
• Covis Pharma (Suiza)
• Zydus Pharmaceuticals, Inc. (Estados Unidos)
• Cipla (India)
• Electromed, Inc. (Estados Unidos)

Últimos avances en el mercado de la bronquiectasia

• En noviembre de 2021, Covis Pharma Group, una empresa farmacéutica especializada global centrada en brindar soluciones de tratamiento para pacientes con afecciones potencialmente mortales y enfermedades crónicas, anunció la adquisición de Eklira (bromuro de aclidinio). Conocido como Tudorza en los EE. UU. y comercializado como Bretaris en varios países, Eklira se utiliza para afecciones respiratorias. Covis Pharma también adquirió Duaklir (bromuro de aclidinio/formoterol), que se comercializa como Brimica en ciertas regiones. Esta adquisición estratégica mejora la cartera de Covis Pharma y fortalece su compromiso de brindar terapias efectivas para la salud respiratoria.

SKU-53983